Genous stent (Orbus Neich) has lower restenosis rate than bare metal stents in ACS treatment

OrbusNeich announced that the company's Genous Stent is associated with a significantly lower rate of binary restenosis compared to bare metal stents (BMS) in low-risk non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients at six months.

Data from JACK-EPC, an investigator-initiated randomized study, were published in the June issue of Minerva CardioangiologicaStent, of which 7.2 percent had cardiogenic shock and 33.1 percent had diabetes.The binary restenosis rate for the Genous Stent was 13 percent compared to 26.6 percent for BMS at six months. At 12 months, the major adverse cardiac events (MACE) rate for the Genous Stent was 13.3 percent compared to 23.3 percent for BMS, and no stent thrombosis (ST) was observed in either group.